Clinical Trial Update: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects [Phase 1]

View source ↗

Summary

This update notes the completion of a Phase 1 randomized, double-blind, placebo-controlled ascending single-dose study of Eisai's E6007 in healthy subjects to c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease

Drugs mentioned

• E6007

Snippet

Sponsor: Eisai Inc. | Conditions: Inflammatory Bowel Disease | Phase 1 | Status: COMPLETED